Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8194169 | 0.81 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL31139029 | 0.80 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2MAOA | |
| SCHEMBL31139004 | 0.80 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2MAOA | |
| SCHEMBL31276323 | 0.80 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2MAOA | |
| SCHEMBL31323890 | 0.79 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2MAOA | |
| SCHEMBL8194171 | 0.78 | SMYD2 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL30977716 | 0.78 | CYP1A2 (0.42) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL26651024 | 0.78 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2MAOA | |
| SCHEMBL9981141 | 0.76 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2MAOA | |
| SCHEMBL5724247 | 0.76 | SMYD2 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025035202-A1 | IONIZABLE LIPIDS COMPRISING MACROCYCLIC RINGS FOR THE DELIVERY OF THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2025-02-20 | — | — | WO | disclosed |